Trending NewsTrending NewsNASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $109.68 +1.24 (+1.14%) Closing price 09/17/2026 04:00 PM EasternExtended Trading$109.78 +0.09 (+0.09%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Halozyme Therapeutics Stock (NASDAQ:HALO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$106.82▼$110.8850-Day Range$75.05▼$110.7652-Week Range$61.22▼$111.15Volume1.98 million shsAverage Volume1.37 million shsMarket Capitalization$12.45 billionP/E Ratio32.74Dividend YieldN/APrice Target$91.20Consensus RatingModerate Buy Company Overview Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion. Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements. The technology has been incorporated into multiple approved therapies, including subcutaneous formulations of treatments for cancer and immune-related conditions. Halozyme also markets Hylenex recombinant, a human hyaluronidase product used to improve the absorption and dispersion of other injected medicines and fluids. Founded in 1998 and headquartered in San Diego, California, Halozyme serves global pharmaceutical markets through its commercial operations and partnerships with drug developers in the United States and internationally. The company’s business model is centered on developing its proprietary delivery platform, licensing it to partners, and supporting the development and commercialization of products that use the technology.AI Generated. May Contain Errors. Read More Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreHALO MarketRank™: Halozyme Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 325th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.Downside RiskHalozyme Therapeutics has a consensus price target of $91.20, representing about 16.8% downside from its current price of $109.68.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth13.09% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 13.09% in the coming year, from $8.25 to $9.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 32.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 32.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.31.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.41. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 261.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.45% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 8.69.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 1.67%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.72 News SentimentHalozyme Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Halozyme Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 6 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,416,633.00 in company stock.Percentage Held by Insiders2.50% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HALO Stock News HeadlinesHalozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033September 17 at 11:20 PM | prnewswire.comHalozyme Therapeutics Unveils $1.05 Bln Offering Of Convertible Notes Due 2033September 17 at 12:02 PM | rttnews.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 18 at 1:00 AM | Banyan Hill Publishing (Ad)Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible NotesSeptember 17 at 7:00 AM | finance.yahoo.comHalozyme announces $1.05B convertible notes offeringSeptember 16 at 5:11 PM | tipranks.comHalozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033September 16 at 4:30 PM | prnewswire.comHalozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of StockSeptember 12, 2026 | insidertrades.comHalozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 SharesAugust 20, 2026 | insidertrades.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $67.30 at the beginning of 2026. Since then, HALO shares have increased by 63.0% and is now trading at $109.68. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The business's revenue for the quarter was up 47.7% on a year-over-year basis. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include these companies: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' top institutional investors include Bank of America Corp DE (2.41%), William Blair Investment Management LLC (2.21%), Royal London Asset Management Ltd. (1.60%) and Jupiter Topco LLC (1.19%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, Mahesh Krishnan, Cortney Caudill and Cortney Caudill. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA). Company Calendar Last Earnings8/06/2026Today9/18/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 HALO's financial health is in the Green zone, according to TradeSmith. HALO has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees423Year Founded1998Price Target and Rating Average Price Target for Halozyme Therapeutics$91.20 High Price Target$115.00 Low Price Target$56.00 Potential Upside/Downside-16.8%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$3.35 Trailing P/E Ratio32.74 Forward P/E Ratio13.29 P/E Growth0.41Net Income$316.89 million Net Margins24.86% Pretax Margin35.06% Return on Equity260.98% Return on Assets23.91% Debt Debt-to-Equity Ratio13.50 Current Ratio2.71 Quick Ratio2.31 Sales & Book Value Annual Sales$1.40 billion Price / Sales8.91 Cash Flow$4.83 per share Price / Cash Flow22.73 Book Value$0.42 per share Price / Book261.14Miscellaneous Outstanding Shares113,500,000Free Float110,661,000Market Cap$12.45 billion OptionableOptionable Beta0.88 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:HALO) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
